Some more interesting news about Amorfix, in our corner Investment Ideas from Readers
On the 11 Sept, Shareholdersunite was kind enough to publish article that I prepared on Amorfix Life Sciences. Just hours ago the company released info that the A4 blood test for Alzheimer’s had been verified by a scientific body. In this press release it was also noticed that for the first time, the company had actually mentioned the Alzheimer’s blood test for humans and also a early blood test to detect liver cancer. They have never been so direct about this program which leads me to believe that they are very close to announcing the completion of these two tests. A blood test to detect Alzheimer’s in humans is worth billions, with a number of biotech and pharmaceutical companies racing to be first .
CHICAGO –(Sept 14) A simple blood test could diagnose Alzheimer’s disease, U.S. researchers said on Monday, a finding that could give more people a chance to be tested.Other teams have shown spinal fluid tests, which require a spinal tap, can detect early changes that signal the onset of Alzheimer’s, which affects at least 26 million people globally. And imaging companies such as privately held Avid Radiopharmaceuticals, General Electric’s GE Healthcare and Germany’s Bayer are racing to finish clinical trials on new agents that can make brain lesions called plaques visible on positron emission tomography or PET scanners.A blood test would make Alzheimer’s diagnosis much simpler, said Sid O’Bryant of Texas Tech University Health Sciences Center in Lubbock.
TORONTO, Sept. 16 /CNW/ – Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases including Alzheimer’s disease (AD), is pleased to announce that data generated by its A4 test has been published in a peer-reviewed scientific publication. The Journal of Alzheimer’s Disease has published the research article entitled: Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer’s Disease of the APP(V717I) London Transgenic Mouse Model by An Tanghe, Annelies Termont, Pascal Merchiers, Stephan Schilling, Hans-Ulrich Demuth, Louise Scrocchi, Fred Van Leuven, Gerard Griffioen, and Tom Van Dooren.
In this paper, among other findings, the authors confirm the validity of the Amorfix A4 assay in detecting aggregated Abeta, which is a neuropathological marker of the “APP London” (APP-Ld) mouse model offered for preclinical in vivo drug testing by reMYND NV. The published data include A4 analysis of the brains from the APP-Ld mice to monitor accumulation of aggregated species of Abeta at ages too young to analyze using conventional methods such as immunohistochemistry.
“This publication of data in a peer-reviewed journal represents a significant milestone for Amorfix in validating the use of the A4 for detection and quantification of aggregated Abeta in pre-clinical models, and is the first of what we hope are many future publications.” said Louise Scrocchi, Associate Director of Research and Development for Amorfix.
reMYND NV and Amorfix have a non-exclusive license that allows reMYND to offer Amorfix A4 analysis of samples to their customers. reMYND’s contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer’s disease (AD).
The Amorfix A4 assay is an ultrasensitive method for the detection of aggregated Abeta that provides quantitative measurements of aggregates. The A4 can detect aggregates in plasma, and brain tissue from standard animal models of AD several months before conventional microscopic procedures thereby accelerating the preclinical screening of new drugs for AD. The A4 is significantly more sensitive than current methods for detecting total Abeta and can be used in high-throughput applications designed to study the inhibition of amyloid formation.
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer’s disease, ALS, and cancer. The Company’s diagnostic programs include an ultrasensitive method for the detection of aggregated Beta-Amyloid in brain tissue and blood from animal models of AD, months prior to observable amyloid formation, as well as human blood screening tests for Alzheimer’s and early liver cancer detection. Amorfix’s proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes (“DSE”) on the molecular surface of misfolded proteins. Amorfix’s lead therapeutic programs include antibodies and vaccines to DSEs in ALS, AD and cancer. For more information about Amorfix, visit www.amorfix.com.